<DOC>
	<DOCNO>NCT02053324</DOCNO>
	<brief_summary>The purpose study assess new treatment patient liver tumor metastasis colorectal cancer . The treatment never use human . The treatment foresees use two compound : AvdinOX [ 177Lu ] DOTA-biotin . AvidinOX new compound , essentially natural protein obtain hen egg , [ 177Lu ] DOTA-biotin new chemical compound result combination DOTA-biotin ( also derive natural vitamin biotin ) 177Lutetium , atom emits radiation . AvidinOX inject directly metastases liver [ 177Lu ] DOTA-biotin inject arm vein . One specific property AvidinOX chemically link tumor tissue inject maintain capacity take [ 177Lu ] DOTA-biotin . Once locally bind tumor tissue , AvidinOX become `` artificial receptor '' intravenously inject [ 177Lu ] DOTA-biotin , allow internal radiation therapy tumor tissue . The treatment liver metastases local injection AvidinOX follow intra-venous injection [ 177Lu ] DOTA-biotin could simpler tolerable current available treatment .</brief_summary>
	<brief_title>AvidinOX + 177LuDOTA-biotin ( 177Lu-ST2210 ) Complex Patients With Liver Metastases From Colorectal Cancer</brief_title>
	<detailed_description>Primary objective 1 . To identify Maximum Tolerated Dose ( MTD ) 177Lu-ST2210 prior intra-lesional injection AvidinOX liver . 2 . To assess safety tolerability intra-lesionally injected AvidinOX + IV inject 177Lu-ST2210 3 . To evaluate intra-lesional distribution retention AvidinOX + 177Lu-ST2210 complex liver metastases 4 . To evaluate systemic biodistribution pharmacokinetics 177Lu-ST2210 { AvidinOX + 177Lu-ST2210 } - complex Secondary objectives 1 . To evaluate proportional 177Lu-ST2210 tumor binding , function total tumor load , AvidinOX dose inject 2 . To demonstrate AvidinOX post-deposition reactivity 177Lu-ST2210 time 3 . To evaluate whole body dosimetry IV 177Lu-ST2210 prior AvidinOX injection ( radiation safety dosimetry ) 4 . To record individual tumor dosimetry 5 . To evaluate preliminary efficacy { AvidinOX + 177Lu-ST2210 } -complex reduce tumor size 6 . To evaluate whole body safety dosimetry dose linearity IV administer 177Lu-ST2210 prior intra-lesional injection AvidinOX 7 . To evaluate pharmacokinetics ST2210 plasma urine</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Biotin</mesh_term>
	<criteria>1 . Male female ≥ 18 year age 2 . Liver metastases histologically confirm colorectal cancer least one liver metastasis ≥ 1 cm ( measurable disease ) , chemoresistant , eligible curative surgery suitable intralesional injection assess investigator . 3 . Total liver tumor burden require ≤ 75 ml AvidinOX 4 . Maximum 9 liver metastasis 5 . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 6 . Life expectancy least 3 month . 7 . Clotting parameter follow , local normal range take reference : Prothrombin Time ( Quick ) .Patients show increase Upper Limit Normal ( ULN ) range 20 % also consider inclusion . International Normalised Ratio ( INR ) . Patients show increase ULN 20 % also consider inclusion Activated Partial Thromboplastin Time ( aPTT ) . Patients show increase ULN 20 % also consider inclusion Fibrinogen . Patients show decrease Lower Limit Normal range ( LLN ) 20 % also consider inclusion . 8 . Haematological , liver renal function test result ≤ grade 2 toxicity ( accord US National Cancer Institute 's `` Common Terminology Criteria Adverse Events v4.03 [ CTCAE ] '' ) , i.e . : Haematology : Haemoglobin ≥ 8 g/dl White blood cell count ≥ 2 x 109/L Platelets ≥ 80x 109/L Liver : Alanine Aminotransferase ( ALT ) , Aspartate Aminotransferase ( AST ) , Alkaline Phosphatase ( AP ) ≤ 5 time upper limit normal Bilirubin ≤ 3 time upper limit normal Renal : Urine protein dipstick : 0 estimate Glomerular Filtration Rate ( eGFR ) &gt; 30 ml/min/1.73 m2 ( CKDEPI formula ) 9 . Written inform consent 1 . Known hypersensitivity Avidin AvidinOX ( e.g . hen egg ) 2 . Known hypersensitivity ST2210 ( DOTA biotin ) excipient . 3 . Life limit metastasis outside liver . Metastases outside liver allow case residual metastasis ( liver treatment ) amenable treatment ( e.g . surgical removal ) 4 . Presence unreachable ( e.g . locate region liver reach needle , close major blood vessel adjacent main organ ) untreatable hepatic lesion benefit treatment treatable lesion justify patient 's inclusion 5 . Active infection screen history severe infection within previous 3 month , clinically relevant screening consider investigator 6 . Known human immunodeficiency virus ( HIV ) positive serology chronically active hepatitis B C. 7 . Administration another investigational medicinal product within 30 day screen period . 8 . Previous treatment Selective Internal Radiation Therapy ( SIRT ) spheres radiopharmaceutical within period correspond 8 halflives radionuclide use label respective radiopharmaceutical prior administration study drug . 9 . Women childbearing potential . A permanent postmenopausal status must prove follow : history hysterectomy hormone analysis serum : estradiol &lt; 20 pg/ml follicle stimulate hormone ( FSH ) &gt; 40 IU/L , amenorrhea start least 1 year prior study start andnegativeβHCG . 10 . Men unwilling use appropriate contraceptive method study six month end study 11 . Inability unwillingness catheterize 12 . History somatic psychiatric disease/condition may interfere objective study 13 . Clinically significant illness clinically relevant trauma within 15 day screen period 14 . Patient underwent chemotherapy , radiation therapy within 15 day screen period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>AvidinOX</keyword>
</DOC>